Immuneering Corporation (IMRX)

Market Cap	314.86M +576.0%
Revenue (ttm)	n/a
Net Income	-56.02M
EPS	-1.27
Shares Out	64.65M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	345,601
Open	4.810
Previous Close	4.860
Day's Range	4.805 - 4.990
52-Week Range	1.100 - 10.080
Beta	0.45
Analysts	Strong Buy
Price Target	17.20 (+253.18%)
Earnings Date	Mar 6, 2026

About IMRX

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinica...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 30, 2021
• Employees: 53
• Stock Exchange: NASDAQ
• Ticker Symbol: IMRX
• Website: https://immuneering.com

Analyst Summary

According to 5 analysts, the average rating for IMRX stock is "Strong Buy." The 12-month stock price target is $17.2, which is an increase of 253.18% from the latest price.

Price Target

$17.2

(253.18% upside)

Analyst Consensus: Strong Buy